The Demographics and Outcomes of Women With Stage II Endometrial Cancer Diagnosed in Australia 2005–2007
Australian and New Zealand Journal of Obstetrics and Gynaecology · 2025
DOI: 10.1111/ajo.70006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australian and New Zealand Journal of Obstetrics and Gynaecology, 2025. Verfasst von Jonathan Sandeford und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Endometrial Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council (NHMRC) of Australia, Cancer Council Tasmania, Cancer Australia Priority-driven Collaborative Cancer Research Scheme.
Abstract (Originalsprache)
Background
Stage II endometrial cancer comprises 5% to 10% of cases and is pathologically diverse. Retrospective data guides recommendations which suggest surgical staging with adjuvant therapy, but the role of radical surgery and lymphadenectomy is uncertain, due to conflicting outcomes. Treatment decisions are influenced by histopathology, yet a definitive standard of care is still elusive.
Objectives
To identify prognostic factors affecting stage II endometrial cancer survival and assess the 2009 FIGO staging changes using data from the Australian National Endometrial Cancer Study (ANECS). Materials and Methods Ninety patients were identified between July 2005 and December 2007. Survival data was analysed using Kaplan–Meier estimates and Cox regression models, with ethics approval from QIMR.
Results
Ninety patients were identified with an average age of 60 and mean body mass index (BMI) of 30. Positive cytology (HR 5.4 [CI: 1.32–22.15]) and chemotherapy alone (HR 17.3) [CI: 2.65–112.6] were identified overall survival (OS) predictors in univariate and age (HR 1.81; [CI: 1.13–2.91]) in multivariate analyses. LVSI was a significant progression free survival (PFS) predictor (HR 4.29; [CI: 1.13–16.26]). There was no significant difference in OS ( p = 0.9) and PFS ( p = 0.6) when cases were re‐stratified into the 1988 stage IIA and IIB groups.
Conclusions
The study supports contemporary management of simple hysterectomy with lymph node assessment and the refined 2009 stage II definition. Current treatment paradigms could also be refined based upon prognostic factors like age and LVSI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Gynaecological Oncology, The Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
- Division of Gynaecological Oncology, National University Hospital, Singapore, Singapore.
ORCID-Profile: Jonathan Sandeford
Förderung
- National Health and Medical Research Council (NHMRC) of Australia
- Cancer Council Tasmania
- Cancer Australia Priority-driven Collaborative Cancer Research Scheme
Zitieren
APA
Sandeford, J., Tong, P., & Pather, S. (2025). The Demographics and Outcomes of Women With Stage II Endometrial Cancer Diagnosed in Australia 2005–2007. Australian and New Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.70006
Vancouver
Sandeford J, Tong P, Pather S. The Demographics and Outcomes of Women With Stage II Endometrial Cancer Diagnosed in Australia 2005–2007. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2025. doi:10.1111/ajo.70006
BibTeX
@article{Sandeford2025,
author = {Sandeford, Jonathan and Tong, Pearl and Pather, Selvan},
title = {The Demographics and Outcomes of Women With Stage II Endometrial Cancer Diagnosed in Australia 2005–2007},
journal = {Australian and New Zealand Journal of Obstetrics and Gynaecology},
year = {2025},
doi = {10.1111/ajo.70006}
}
EUVIMED